DarioHealth Granted License by Health Canada to Sell Dario Smart Glucose Meters for Lightning® Connector Enabled iPhones

Significant expansion of Dario's Canadian market opportunity to include iPhone 7, 8, and iPhone X user

News provided by

Mar 20, 2019, 08:30 ET

NEW YORK and CAESAREA, Israel, March 20, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), announced today the receipt of a license from Health Canada to sell its Dario™ Blood Glucose Monitoring System for Lightning power connector-enabled iPhone smart mobile devices.

iPhone users in Canada, including those with prior models that use a headphone jack, as well as those with the Lightning power connector, will now have access to DarioHealth's acclaimed digital diabetes products and lifestyle management app features, like glucose level tracking, real time patient glucose data access for healthcare providers, carb counting, hypo alerts, amongst other diabetes countering features.

DarioHealth has marketed the product in Canada exclusively for Apple iOS 6.1 platform and higher, and for leading Android devices since receiving a license from Health Canada in May 2015.

With this license, DarioHealth's addressable Canadian market expands to include the entire iPhone user base.

"Recognizing the importance of access to the entire iPhone market in Canada, we prioritized this initiative to meet Health Canada's rigid licensing standards, and our team worked tirelessly to achieve it," commented Erez Raphael, DarioHealth's CEO. "Not only will this access a large segment of new users, but it will allow our existing Canadian users who have upgraded their iPhones to reconnect with our life enhancing services."

About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by data, high quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way. Our Cross Functional Team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that Health Canada license for iPhone devices opens a significant market opportunity, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
[email protected]
+1-914-775-5548

SOURCE DarioHealth Corp.